President Trump's proposed tariffs on pharmaceuticals have raised questions about which companies will be affected. While the specifics remain unclear, it appears that many of the largest drugmakers may receive exemptions. Notably, Merck has begun construction on a new factory in Delaware, which could position the company to benefit from a partial exemption. This situation highlights the ongoing complexities in the pharmaceutical industry and the potential implications for drug pricing and availability.

President Trump's proposed pharmaceutical tariffs have prompted many of the world's wealthiest drugmakers to express confidence that they will remain unaffected by these levies. In anticipation of potential tariffs, these companies are proactively committing to invest billions in domestic manufacturing. This move is significant as it highlights the ongoing tension between government policies and the pharmaceutical industry, while also emphasizing the industry's efforts to adapt and maintain stability in a changing economic landscape.